Improving Biomarker Driven Precision Therapy in NSCLC: Less Common, More Complex: Multidisciplinary Discussion of Safety and Efficacy of TKIs for Rare Mutations in NSCLC October 4, 2022

How to Claim Your Credit/Certificate  Credit will be awarded to those attendees who attend the webinar and complete their evaluation.
  1. To claim CME, CNE or  participation credit, go to https://cme.bu.edu/NSCLCPart5
  2. Click on Take Course and you will be directed to Login or Create an Account.
  3. If you have a BU or BMC e-mail, you may log-in using Single Sign On (SSO) with your username and password. Otherwise, click Create a New Account or Log-in.
  4. Click on “Take Course” and your enrollment with be recorded. You will now see a Course Progress box. Complete any requirements to claim your credit (e.g., the evaluation form). Clicking Next in the Course Navigation box will guide you through each element. The Credit section will confirm the credit type you were awarded.
  5. Pharmacists who watch the one-hour webinar will be sent an email with how to claim credit. Please email cgrimble@bu.edu if you do not see this email.
  6. All Credit must be claimed within 60 days.
  7. Questions? Phone: 617-358-5005. Email: cme@bu.edu
     

Biomarker based testing and precision medicine based approaches have become a standard to guide treatment decisions for metastatic non-small cell lung cancer (NSCLC) and are crucial even for early stage/resected patients. There are several barriers that prevent optimal testing for patients, but the discovery of novel molecular targets and subsequent development of targeted therapies make it critical to find ways to overcome these barriers. As treatment progresses, there is a potential to develop resistance mechanisms to commonly used targeted therapies; these new targets are identified by the integration of precision medicine.


There are more complex, rare genomic alterations in NSCLC that warrant further discussion on their impact in clinical practice based on new data. It is imperative for all members of the lung cancer treatment team (oncologists, pathologists, pharmacists, nurse practitioners, nurses, and physicians’ assistants) to understand this data and recognize the complexity of managing these patients using a precision medicine based approach in both first line and subsequent line therapies.


At this webinar, learn clinical pearls needed to attain best outcomes for your patients with these mutations in a case-based conversation with expert faculty.

  • Overview of NSCLC and Transition Towards Biomarker Based Testing
  • Considerations Before Treatment Initiation with RET, MET, KRASG12C, and HER-2-Directed Therapy
  • Treatment Management Pearls During Therapy
     

Goals, Gaps in Practice, and Learning Objectives
The overall goal of this project is to help identify critical gaps in standard biomarker testing and help improve understanding of targeted based therapies for patients with non-small cell lung cancer (NSCLC). Furthermore, this educational series would allow oncology team members to become more familiar with the targeted based approaches for less common mutations and make treatment decisions to promote better care for patients.

This program is supported by an educational grant from Pfizer Inc. 

Target Audience

The primary audience targeted with this educational series includes the lung cancer care team. This encompasses medical oncologists, pathologists, interventional radiologists, pharmacists, nurse practitioners, physicians’ assistants, and nurses involved with the care of patients with NSCLC.

Learning Objectives

At the end of this program, attendees should be able to:

  • Identify operational and clinical barriers that may interfere with optimal biomarker based testing and develop initiatives to offset these barriers
  • Describe first and subsequent line targeted treatment approaches for adult patients with metastatic RET, KRASG12C, and MET and HER-2-altered NSCLC
  • Discuss strategies to mitigate adverse effects of treatment to improve long-term survival and quality of life for patients with RET, KRASG12C, MET and HER-2 altered NSCLC
     
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.25 ANCC
  • 1.00 Participation
Course opens: 
10/04/2022
Course expires: 
12/05/2022

This session will take place virtually through Zoom on Tuesday October 4, 2022 from 5-6pm ET

At this webinar, learn clinical pearls needed to attain best outcomes for your patients with these mutations in a case-based conversation with expert faculty.

  • Overview of NSCLC and Transition Towards Biomarker Based Testing

  • Considerations Before Treatment Initiation with RET, MET, KRASG12C, and HER-2-Directed Therapy

  • Treatment Management Pearls During Therapy

 

 

 

Speakers

Jasmine Patel, PharmD, BCOP
Clinical Pharmacy Coordinator – Hematology/Oncology
Boston Medical Center


Dr. Patel is a clinical pharmacy coordinator in the outpatient hematology/oncology clinic at Boston Medical Center and is currently the program director for the PGY2 residency program. In her first year at the institution, Jasmine co-led an initiative with our lead breast cancer oncologist (Dr. Naomi Ko, MD, MPH) to improve adherence and toxicity management of patients treated with oral chemotherapy for metastatic breast cancer. She was additionally awarded "Resident of the Year" for her dedication to her oncology patients and the pharmacy profession. Dr. Patel runs day-to-day pharmacy efforts by routinely calling and managing patients and assisting with PRO documentation within our EMR.

Speaker receives grant funding from Pfizer Inc. for breast cancer research

Bhavesh Shah R.Ph, BCOP
Chief Pharmacy Officer for Specialty and Hematology/Oncology Pharmacy Services
Boston Medical Center Health System

Bhavesh Shah, R.Ph, BCOP, earned a bachelor of science in pharmacy degree at Massachusetts College of Pharmacy and Health Sciences subsequent to receiving a biochemistry degree from Loyola University Chicago. A board-certified oncology pharmacist, Mr. Shah is presently the Chief Pharmacy Officer for Specialty and Hematology/Oncology Pharmacy Services at Boston Medical Center Health System.   In this role, he is responsible for the clinical, research, payor and manufacturer contracting and operational efficiency of the cancer center, specialty pharmacy, and various ambulatory specialty areas.  Mr. Shah also oversees clinical support for specialty programs for a regional managed care medicaid plan with over 400,000+ lives and $550 million service line. 
He has research experience is in COVID-19, biosimilars, cancer-related anorexia and cachexia syndrome, prevention of chemotherapy-induced nausea and vomiting, treatment of iron deficiency anemia, lung cancer digital adherence technology, immune thrombocytopenia purpura, and inflammatory bowel disease. He is a reviewer for the Annals of Pharmacotherapy, American Journal of Health System Pharmacy  and has written articles in the Journal of Oncology Pharmacy Practice, Supportive Care in Cancer, and Biology of Blood and Marrow Transplantation.  Mr. Shah has presented both nationally and internationally on biosimilars, specialty pharmacy arena, 340b, and the field of hematology/oncology pharmacy.  

Speaker receives grant/research support from Pfizer, Alexion, Fujifilm and Rigel

Umit Tapan, MD
Thoracic Medical Oncologist
Co-Director, Thoracic Oncology Program, Boston Medical Center
Assistant Professor of Medicine, Boston University Chobanian & Avedisian School of Medicine

Dr. Tapan is an Assistant Professor of Medicine at Boston University School of Medicine and a practicing Thoracic Oncologist at Boston Medical Center. He currently co-leads BMC thoracic oncology program and is the site-PI for clinical trials in thoracic malignancies. As a productive clinical researcher Dr. Tapan has authored numerous publications. His previous research efforts focusing on the role of c-cbl in pathophysiology of colorectal cancer have been published in prestigious journals. Dr. Tapan has been interested in racial disparity in cancer care since early years of his career and he has previously shown that African American patients with colorectal cancer have significantly lower survival despite equal access to care. His current research interests are racial disparities in lung cancer care, access to targeted treatments and immune checkpoint inhibitors in vulnerable populations. Most recently looking at disparities in chemotherapy receipt in extensive stage small cell lung cancer. (https://www.jtocrr.org/article/S2666-3643(20)30155-7/fulltext)

Speaker is an outside consultant for GSK, receives grant/research support from Pfizer.

Planning Committee

Dana F. Price, MS, CHCP
Grants and Development Manager
Continuing Medical Education Office Boston University School of Medicine

David Hughes, PharmD, BCOP
Course Director
Clinical Pharmacy Manager Hematology/Oncology
Boston Medical Center

Jasmine Patel, PharmD
Clinical Pharmacy Specialist – Hematology/Oncology
Boston Medical Center

Umit Tapan, MD
CME Course Director
Assistant Professor of Medicine, Department of Medicine, Boston University School of Medicine

Elizabeth Tiani, AGACNP
NCPD Course Advisor
Instructor of Medicine, Medical Oncology
BUSM/BMC

Carmela A. Townsend, DNP, MS/MBA, RN
Accredited Provider Activity Director
Continuing Medical Education Office Boston University School of Medicine

Planners have nothing relevant to disclose.

CME Program Manager:  Claire P. Grimble, CMP

Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Boston University School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Boston University School of Medicine Continuing Nursing Education is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

CONTINUING EDUCATION CREDITS

The University of Rhode Island College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  This is an application-based educational activity. Pharmacists will receive 1.0 contact hours (0.10 CEUS) for the educational activity. No partial credit is available.

UNIVERSAL ACTIVITY NUMBERS (UAN) 0060-9999-21-029-L01-P        

Available Credit

  • 1.00 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.25 ANCC
  • 1.00 Participation
Please login or register to take this course.